Arcus, Gilead prep Phase III studies of anti-TIGIT domvanalimab
Preparations come on the heels of positive results from the Phase II ARC-7 study
Read More
Tag: Arcus Biosciences
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
